---
title: Peripheral Vascular Devices Industry, Global, 2024–2029
description: Innovations in Drug-eluting Stents and Drug-coated Balloons are Driving Transformational Growth
image: https://go.frost.com/hubfs/Images/2025/HLS/GO/KB45/R01_HLS%20GO%20KB45%20PeripheralVascular_061125_JY_AK3.jpg
---

![R01_HLS GO KB45 PeripheralVascular_061125_JY_AK2 (1)](https://go.frost.com/hs-fs/hubfs/Images/2025/HLS/GO/KB45/R01_HLS%20GO%20KB45%20PeripheralVascular_061125_JY_AK2%20(1).jpg?width=2000&height=400&name=R01_HLS%20GO%20KB45%20PeripheralVascular_061125_JY_AK2%20(1).jpg "R01_HLS GO KB45 PeripheralVascular_061125_JY_AK2 (1)")

*Peripheral Vascular Devices Industry: A $6 Billion Race to Lead in Innovation and Outcomes*

From peripheral artery disease (PAD) to chronic limb-threatening ischemia (CLTI), drug-eluting and bioresorbable technologies are transforming care pathways. Will your organization lead the charge?

[ Instant Access ](https://store.frost.com/peripheral-vascular-devices-industry-global-2024-2029.html?utm_source=hs_email&utm_medium=email&utm_term=GL_OU_HLS_GO_KB45_RD1_Jun25&utm_campaign=HLS03_TG09_KB45_Jun25)

Market Momentum

PAD affects 200+ million people globally — but with low screening and diagnosis rates, this market remains vastly underpenetrated. As demand for minimally invasive, endovascular interventions soars, the industry is shifting toward:

- **Drug-eluting Stents (DES)**
- **Drug-coated Balloons (DCBs)**
- **Bioresorbable Scaffolds**
- **Advanced Imaging and Robotics**

Projected Market Value:

- From **$4.3 billion in 2024 to $6.06 billion in 2029**
- CAGR: **6.9%**

### Download Sample

Strategic Insights You Will Gain

### **Technology Intelligence**

•    First-in-human milestones (e.g., ChampioNIR, Esprit BTK)

•    R3 Vascular’s IDE-backed MAGNITUDE trial

•    Positive long-term results from Abbott’s bioresorbable portfolio

### **Opportunities to Act On**

•    Growth in below-the-knee interventions for **chronic limb-threatening ischemia (CLTI)**

•    Clinical adoption in **ambulatory surgical centers (ASCs)**

•    Innovation gaps in **resorbable scaffolds** and **device-drug synergy**

### **Competitive Landscape**

•    Market share and positioning of Boston Scientific, Abbott, BD, Medtronic, and emerging disruptors

•    Strategic M&A activity: Acotec, Cardiovascular Systems Inc.

### Sign up for a complimentary Growth Pipeline Dialog™

A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.

Upon completing the dialog session, you will receive a $1,000 honorarium* as a token of our appreciation, which can be used towards the purchase of our products and services on [store.frost.com](https:/store.frost.com?utm_source=hslinks).

[ Talk to our experts today! ](https://insights.frost.com/gpdialog?hsCtaTracking=2540db65-be35-44dd-abb4-f667210b0fde%7C973ed019-8950-4e26-8c86-4b58d2df9b85&hsLang=en)

*$1,000 honorarium is subject to eligibility

![drive-growth-image-scaled-2](https://go.frost.com/hubfs/Imported%20sitepage%20images/drive-growth-image-scaled-2.jpg "drive-growth-image-scaled-2")

**